PER® New York Lung Cancer Symposium | Conference

Dr. Owonikoko on Standard of Care for SCLC

November 15th 2019

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

Dr. Kelly on Determining Second-Line TKI in Lung Cancer

November 14th 2019

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

NGS Testing Is Essential Before Induction in NSCLC

November 12th 2019

Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.

Dr. Borghaei on the Search for Biomarkers in Lung Cancer

November 12th 2019

Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.

Dr. Halmos on Actionable Biomarkers in NSCLC

November 12th 2019

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer

November 12th 2019

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Plasma NGS Demonstrating Practice-Changing Potential in NSCLC

November 12th 2019

Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.

Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC

November 12th 2019

Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC

November 10th 2019

Suresh S. Ramalingam, MD, FASCO, discusses updated data from the FLAURA trial in EGFR-mutant non–small cell lung cancer.

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

November 10th 2019

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Role of Neoadjuvant Immunotherapy Being Refined in Resectable NSCLC

November 10th 2019

Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.

Neoadjuvant Approaches Showcase Advantages in NSCLC

November 10th 2019

Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.

Levy Lends Insight on Evolving Treatment Strategies in Lung Cancer

November 9th 2019

Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.

More Data Needed on Changing Systemic Therapy in NSCLC

November 13th 2018

There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.

Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options

November 13th 2018

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

Herbst Highlights Next Steps With Immunotherapy in Lung Cancer

November 13th 2018

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

Dr. Hanna on Consolidation Immunotherapy in Stage III NSCLC

November 13th 2018

Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12th 2018

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Broad Panel NGS Testing Grows in Value for NSCLC

November 11th 2018

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

Dr. Perez-Soler on Efficiency of NGS in Lung Cancer

November 11th 2018

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the efficiency of next-generation sequencing in lung cancer.